Business
Why the Telix (ASX:TLX) share price is surging 8%

Telix Pharmaceuticals Ltd (ASX: TLX) shares are rocketing higher this morning after the company announced the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for a prostate cancer imaging product. In early morning trade, the Telix share price is trading 8.1% higher at $3.07.
NDA approval
Investors are driving up the Telix share price today after news that the FDA has accepted the company’s NDA for TLX591-CDx (kit for the preparation of Ga-PSMA-11). The prostate cancer imaging product is a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). It uses a Positron Emission Tomography (PET) to scan for the disease.
Telix’s NDA submission for its prostate cancer imaging…
-
Noosa News23 hours ago
Mega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News16 hours ago
NRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General16 hours ago
How the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News7 hours ago
New playground equipment encourages children to learn through ‘risky play’